RECRUITING

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Conditions

Refractory Multiple Myeloma Selinexor Lenalidomide-Refractory Multiple Myeloma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

Official Title

A Pilot Study Examining Selinexor's Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Quick Facts

Study Start:2020-11-01

Study Completion:2023-12-29

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04519476

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients must meet all of the following inclusion criteria to be eligible to enroll in this study: 1. Age ≥ 18 year of age. 2. Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. ECOG Performance Status (PS) of ≤ 2. 5. Has a diagnosis of MM based on standard criteria (9) as follows: 1. Plasmacytomas on tissue biopsy. 2. Bone marrow plasmacytosis (greater than 30% plasma cells). 3. Monoclonal immunoglobulin spike on serum electrophoresis IgG greater than 3.5 g/dL or IgA greater than 2.0 g/dL or kappa or lambda light chain excretion greater than 1 g/day on 24-hour urine protein electrophoresis. 1. Bone marrow plasmacytosis (10% to 30% plasma cells). 2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria. 3. Lytic bone lesions. 4. Normal IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL. 6. Currently has MM with measurable disease, defined as: * a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or * urine monoclonal protein levels of at least 200 mg/24 hours * for patients without measurable serum and urine M-protein levels, an involved SFLC \> 100 mg/L or abnormal SFLC ratio 7. Currently has progressive MM: MM patients that are relapsed or have refractory disease from at least 3 regimens or lines of therapy are eligible for enrollment provided they fulfill the other eligibility criteria: * patients are considered relapsed, when they progress greater than 8 weeks from their last dose of treatment * patients are refractory when they progress while currently receiving the treatment or within 8 weeks of its last dose 8. Previous exposure to lenalidomide: failed lenalidomide (\> 10 mg)-containing regimen (lenalidomide- containing regimen could be any prior regimen and is not required to be a part of their most recent treatment) and have received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody therapy. 9. Adequate hepatic function within 28 days prior to C1D1: Total bilirubin \< 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 × ULN), and Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to \< 2 × ULN. 10. Adequate renal function within 28 days prior to C1D1 as determined by serum creatinine of ≤1.5 mg/dL OR estimated CrCl of \> 60 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female (10)(Appendix 5). 11. Adequate hematopoietic function within 7 days prior to C1D1: total WBC count ≥1500/mm3, ANC ≥1000/mm3, hemoglobin ≥8.5 g/dL and platelet count ≥75,000/mm3 (patients for whom \<50% of BM nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of BM nucleated cells are plasma cells). 12. Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, G-CSF, GM-CSF, and platelet stimulators (e.g., eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study. 13. Patients must have: * At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the start of study treatment * At least a 1-week interval from the last platelet transfusion prior to the start of study treatment * However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study 14. Patients must be registered into the mandatory REVLIMID REMS™ program and be willing and able to comply with the requirements of the REVLIMID REMS™ program. 15. Female patients of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment, specifically: * FCBP† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting treatment and must either commit to continued abstinence from heterosexual intercourse or use acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, and at least 28 days before she starts therapy. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. * A FCBP (female of childbearing potential) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Able to take aspirin (acetylsalicylic acid, ASA) at 81 or 325 mg/daily as antiplatelet therapy if platelet count is above 30 x 109/L (subjects intolerant to ASA may use warfarin or low molecular weight heparin)	* Patients meeting any of the following exclusion criteria are not eligible to enroll in this study: 1. Has received selinexor or another XPO1 inhibitor previously. 2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \>5 years previously and without evidence of recurrence will be allowed. 3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\], primary amyloidosis, etc.) that is likely to interfere with study procedures. 4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable. 5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids. 6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids. 7. Concurrent use of other anti-cancer agents or treatments. 8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. 9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin 10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. 11. Pregnant or breastfeeding females. 12. BSA \<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method. 13. Life expectancy of less than 3 months. 14. Major surgery within 4 weeks prior to C1D1. 15. Active, unstable cardiovascular function, as indicated by the presence of: 1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen. 18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment. 19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care). 20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent. 21. Contraindication to any of the required concomitant drugs or supportive treatments. 22. Patients unwilling or unable to comply with the protocol.

Inclusion Criteria

Exclusion Criteria

* Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
1. Age ≥ 18 year of age.
2. Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. ECOG Performance Status (PS) of ≤ 2.
5. Has a diagnosis of MM based on standard criteria (9) as follows:
1. Plasmacytomas on tissue biopsy.
2. Bone marrow plasmacytosis (greater than 30% plasma cells).
3. Monoclonal immunoglobulin spike on serum electrophoresis IgG greater than 3.5 g/dL or IgA greater than 2.0 g/dL or kappa or lambda light chain excretion greater than 1 g/day on 24-hour urine protein electrophoresis.
1. Bone marrow plasmacytosis (10% to 30% plasma cells).
2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria.
3. Lytic bone lesions.
4. Normal IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL.
6. Currently has MM with measurable disease, defined as:
* a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or
* urine monoclonal protein levels of at least 200 mg/24 hours
* for patients without measurable serum and urine M-protein levels, an involved SFLC \> 100 mg/L or abnormal SFLC ratio 7. Currently has progressive MM: MM patients that are relapsed or have refractory disease from at least 3 regimens or lines of therapy are eligible for enrollment provided they fulfill the other eligibility criteria:
* patients are considered relapsed, when they progress greater than 8 weeks from their last dose of treatment
* patients are refractory when they progress while currently receiving the treatment or within 8 weeks of its last dose 8. Previous exposure to lenalidomide: failed lenalidomide (\> 10 mg)-containing regimen (lenalidomide- containing regimen could be any prior regimen and is not required to be a part of their most recent treatment) and have received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody therapy.
9. Adequate hepatic function within 28 days prior to C1D1: Total bilirubin \< 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 × ULN), and Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to \< 2 × ULN.
10. Adequate renal function within 28 days prior to C1D1 as determined by serum creatinine of ≤1.5 mg/dL OR estimated CrCl of \> 60 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female (10)(Appendix 5).
11. Adequate hematopoietic function within 7 days prior to C1D1: total WBC count ≥1500/mm3, ANC ≥1000/mm3, hemoglobin ≥8.5 g/dL and platelet count ≥75,000/mm3 (patients for whom \<50% of BM nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of BM nucleated cells are plasma cells).
12. Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, G-CSF, GM-CSF, and platelet stimulators (e.g., eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study.
13. Patients must have:
* At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the start of study treatment
* At least a 1-week interval from the last platelet transfusion prior to the start of study treatment
* However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study 14. Patients must be registered into the mandatory REVLIMID REMS™ program and be willing and able to comply with the requirements of the REVLIMID REMS™ program.
15. Female patients of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment, specifically:
* FCBP† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting treatment and must either commit to continued abstinence from heterosexual intercourse or use acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, and at least 28 days before she starts therapy. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
* A FCBP (female of childbearing potential) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Able to take aspirin (acetylsalicylic acid, ASA) at 81 or 325 mg/daily as antiplatelet therapy if platelet count is above 30 x 109/L (subjects intolerant to ASA may use warfarin or low molecular weight heparin)

* Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:
1. Has received selinexor or another XPO1 inhibitor previously.
2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \>5 years previously and without evidence of recurrence will be allowed.
3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\], primary amyloidosis, etc.) that is likely to interfere with study procedures.
4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.
6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.
7. Concurrent use of other anti-cancer agents or treatments.
8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin
10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
11. Pregnant or breastfeeding females.
12. BSA \<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.
13. Life expectancy of less than 3 months.
14. Major surgery within 4 weeks prior to C1D1.
15. Active, unstable cardiovascular function, as indicated by the presence of:
1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.
18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.
19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).
20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.
21. Contraindication to any of the required concomitant drugs or supportive treatments.
22. Patients unwilling or unable to comply with the protocol.

Contacts and Locations

Study Contact

Noemi Silagan, MD

CONTACT

(310)623-1204

NSilagan@oncotherapeutics.com

Tanya Spektor, PhD

CONTACT

(323)251-5941

tspektor@oncotherapeutics.com

Principal Investigator

James R Berenson, MD

PRINCIPAL_INVESTIGATOR

Oncotherapeutics

Study Locations (Sites)

James R Berenson, MD, Inc.

West Hollywood, California, 90069

United States

Collaborators and Investigators

Sponsor: Oncotherapeutics

James R Berenson, MD, PRINCIPAL_INVESTIGATOR, Oncotherapeutics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-11-01

Study Completion Date2023-12-29

Study Record Updates

Study Start Date2020-11-01

Study Completion Date2023-12-29

Terms related to this study

Keywords Provided by Researchers

Selinexor
Lenalidomide-Refractory
Multiple Myeloma

Additional Relevant MeSH Terms

Refractory Multiple Myeloma